EOLS · Evolus, Inc.

The thesis

Evolus's operating case survives, but the shares do not yet reflect it. Revenue grew 21% in the second quarter and adjusted earnings stayed positive, but the stock closed at $7.69 on 1 October 2026, below the $8.00 level it lost on 11 September 2026. The third-quarter report, expected around 4 November 2026, will show whether the $330–337 million revenue outlook and the 67.0–67.5% adjusted gross margin hold once a 15% tariff applies to its Korea-made Jeuveau.

The narrative is maturing. Analysts know the story and cover it steadily, but no published price target has changed since H.C. Wainwright reiterated $13 on 25 August 2026. The only company news since late September is a charity campaign launched on 1 October 2026.

Bullish and bearish views on Evolus, Inc.

The bull case on Evolus, Inc. (EOLS), in brief: Revenue growth is running ahead of estimates. The bear case: The shares lost the $8.00 level.

Bull case

• Revenue growth is running ahead of estimates. On 5 August 2026 Evolus reported second-quarter net revenue of $84.1 million, up 21% year over year, against a consensus estimate near $81.6 million. Management raised the low end of its 2026 revenue outlook to $330–337 million from $327–337 million.
• Adjusted earnings have turned positive. The same release reported $4.7 million of second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA). That was $12.6 million better than a year earlier and the third positive quarter in a row.
• Sell-side support is intact. As of 2 October 2026, stockanalysis.com showed six analysts with an average target of $15, in a range of $12 to $20. Leerink Partners kept its Buy rating on 17 September 2026, and Stifel reiterated a $17 target on 6 August 2026.
• A second filler approval is pending. According to Dermatology Times, Evolus filed a premarket approval application with the Food and Drug Administration (FDA) for its Evolysse Sculpt mid-face filler, and the company expects a decision in the second half of 2026. Approval would add a product to the dermal filler line beside Jeuveau.

Bear case

• The shares lost the $8.00 level. The stock closed at $7.84 on 11 September 2026 and at $7.69 on 1 October 2026. It has not closed back above $8.00 since, despite the August guidance raise.
• The tariff now affects the cost of goods. Crowell & Moring reported on 5 September 2026 that products from the Republic of Korea carry a 15% Section 232 pharmaceutical tariff. Management said in May that the duty applies to Jeuveau from 29 September 2026, and that it imported roughly a year of inventory before that date.
• Profit under accounting rules still lags. On 5 August 2026 Evolus reported a second-quarter operating loss of $4.5 million under generally accepted accounting principles (GAAP), and adjusted earnings per share (EPS) of -$0.12 against a -$0.04 consensus. About 120 basis points of gross margin came from a tariff refund that will not recur.
• Any equity sold under that shelf would dilute existing holders.

Price setup

The 1 October 2026 close of $7.69 was 17.3% below the $9.30 52-week high and 10.0% above its level three months earlier. The 14-day relative strength index (RSI) read 45.3, up from 25.5 at the 25 September 2026 close. The selling pressure has eased, but the price has not recovered.

Crowding evidence points to supply. Chief Executive David Moatazedi sold 105,108 shares on 2 September 2026 for $950,018, at $9.00–$9.13, according to a Form 4 summarised by Investing.com. The shares have not traded at that price since. Retail attention appears limited, and the next results date is about a month away.

Catalysts, next 30 days

• No company-confirmed event falls between 2 October 2026 and 1 November 2026. Evolus usually announces its results date a few weeks before it reports.
• ~4 November 2026, est.: third-quarter 2026 results. MarketBeat estimates this date, and the company has not confirmed it. This is the first quarter with the 15% Korea tariff in effect. It will show whether the $330–337 million revenue outlook and the 67.0–67.5% adjusted gross margin survive.
• Second half of 2026, undated: FDA decision on Evolysse Sculpt. This is the company's expected window as reported by Dermatology Times. A delay into 2027 would push back the filler portfolio's next growth step.

What would change the view

The case breaks on any of three outcomes:

• Evolus cuts its 2026 revenue outlook below $330 million.
• It lowers adjusted gross margin guidance below 67.0% because of import duties.
• It sells equity under the $250 million shelf at prices near the current range.

On price, a daily close below $7.00 would mark a further leg down from the 1 October 2026 close of $7.69 and leave the August guidance raise without support in the shares.

The read would improve if the third-quarter report reaffirms or raises the outlook with margins intact after the tariff, and the shares then close back above $8.00.

What it trades with

Evolus is a small-cap, self-pay aesthetics company. Demand depends on consumer spending on elective treatments, and Jeuveau competes with AbbVie's Botox and Galderma's Dysport. Institutional ownership was 90.69% on 11 August 2026, so the shares tend to move with small-cap risk appetite and with block trades by funds more than with large-cap pharma. Tariff headlines on Korea-origin pharmaceuticals affect Evolus directly, because its drug substance comes from Daewoong in South Korea.